A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple

Noa Biran1, Eli Zolotov2, David Vesole3

  • 1John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; Division of Multiple Myeloma, Hackensack University Medical Center, Hackensack, NJ, USA; Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ. Noa.Biran@hmhn.org.

Haematologica
|April 3, 2025
PubMed
Abstract

No abstract available in PubMed .